Sanofi-aventis strengthens its commitment to research in France through a partnership with AVIESAN Sanofi-aventis signs agreement with Aviesan alliance
This inaugural partnership agreement was signed with the whole of the French academic research community. It concerns the financing of young researchers awarded grants as part of the Inserm/CNRS ATIP AVENIR programme, and the investment of up to 50 million euros over five years for all public-private partnerships.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) today announced the signature of a research partnership with AVIESAN, the national alliance for life and health sciences, composed of the CEA, the CNRS, INRA, Inria, Inserm, the Institut Pasteur, the IRD, the Conference of University Presidents and the Conference of Managing Directors of Regional and University Hospitals. This is the first time that such a partnership has been signed with the entire French academic research community in the field of healthcare.
The aim of this research partnership with AVIESAN is to advance scientific knowledge in the field of life and health sciences, to contribute to the excellence and strengthening of French research, and to develop ambitious projects to serve patients, in areas of research such as ageing, immuno-inflammation, infectious diseases and regenerative medicine. In order to stimulate creativity, teams, laboratories, technology platforms and even research centres common to Sanofi-aventis and the members of AVIESAN may be envisaged.
Sanofi-aventis has also signed a sponsorship agreement in support of the CNRS/Inserm ATIP AVENIR programme, to help support young researchers who wish to set up a research laboratory in France. Sanofi-aventis will finance the beneficiaries of the programme through an annual allowance, in order to encourage collaboration and interaction between researchers working in public research and those from the pharmaceutical industry.
These agreements are part of the objective set by the Strategic Council for the Healthcare Industries [Conseil Stratégique des Industries de Santé (CSIS)] to significantly reinforce partnerships between industrial operators and academic research laboratories, in order to support innovation in Healthcare. To meet this ambitious objective, Sanofi-aventis has undertaken to allocate a budget of up to 50 million euros to these partnerships over 5 years.
« We are very happy to have agreed this partnership with the national alliance for life and health sciences, which represents a major step forward in relations between the public and private sectors in France,» said Christopher A. Viehbacher, CEO of Sanofi-aventis. « By pooling the creativity and expertise of numerous world-renowned researchers, we firmly believe that the fruitful exchanges that will emerge from this collaboration will stimulate innovation in life sciences in France, and lead to major discoveries that benefit the patient. Through this agreement, Sanofi-aventis is once again confirming its commitment to the development of research and innovation in France ».
« We are delighted to announce this overarching partnership with Sanofi-aventis, one of the world leaders in healthcare,’ said Professor André Syrota, Chairman of AVIESAN. ‘The partnership we have signed today with a first-rate player from the drugs industry should allow us to better exploit the results of French research internationally. We are very happy to be working alongside Sanofi-aventis to conduct research concerning matters ranging from the theoretical to the health of patients ».
AVIESAN - national alliance for life and health sciences
The national alliance for life and health sciences (AVIESAN) is made up of the CEA (French Atomic Energy Commission), the CNRS (the French National Centre for Scientific Research), INRA (the French National Institute for Agricultural Research), Inria (the National Institute for Research in Computer Science and Control), Inserm (the National Institute for Health and Medical Research), the Institut Pasteur, the IRD (Institute of Research for Development), the CPU (Conference of University Presidents) and the Conference of Managing Directors of Regional and University Hospitals. AVIESAN’s goal is to develop a continuum leading from theoretical research to its applications at the highest possible level in all fields of life and health sciences research. The national alliance for life and health sciences is organised into ten Thematic Multi-Organisation Institutes, whose role is to coordinate research and to establish an inventory of French research by major theme.
The ATIP AVENIR sponsorship programme (Thematic and Incentivising Action on Programmes for the Future) is a scheme created as part of a partnership between the CNRS and Inserm. Each year, the CNRS and Inserm put out a joint call for proposals to allow young researchers of any nationality who have defended their PhD in the last ten years to create and lead a team within an existing CNRS or Inserm structure.
Sanofi-aventis is a world leader in the pharmaceutical industry which researches, develops and distributes therapeutic solutions to improve the lives of everyone. The Group is listed on the stock exchange in Paris (EURONEXT PARIS: SAN) and in New York (NYSE: SNY) For further information, see the site: www.sanofi-aventis.com.